NCT00153010已完成2 期
A Phase II Double-Blind, Randomized, Dose-Ranging, Placebo-Controlled, Multicenter, Safety and Efficacy Evaluation of Three Doses of NS 2330 in Patients With Mild to Moderate Dementia of the Alzheimer's Type
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 430
- 试验地点
- 87
- 主要终点
- Changes in Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog)
研究概览
简要总结
Objectives: The objective of this study will be to determine the safety, tolerability, drug blood levels, and efficacy of each of three doses of NS 2330 (Tesofensine) given once daily compared with placebo in patients with mild to moderate Dementia of the Alzheimer's Type.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 40 Years 至 85 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients may be included in this study if they meet all of the following criteria:
- •Male, and female without child bearing potential between 40 and 85 years of age, inclusive. Women who have been postmenopausal for less than 2 years must have a negative pregnancy test at screening.
- •Diagnosis of probable mild to moderate Dementia of the Alzheimer's Type as defined by National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association (NINCDS ADRDA) guidelines.9
- •Mini-Mental State Examination (MMSE) score of 10-24 and Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog) score greater than 12 at screening.
- •Modified Hachinski Scale10 score no greater than
- •Central nervous system imaging (CT or MRI scan of brain) compatible with Dementia of the Alzheimer's Type within the past year (also see
排除标准
- •Exhibits reliability and physiologic capability sufficient to comply with all protocol procedures. Patient must be familiar with and fluent in English (i.e., sufficient to complete all study assessments from the language perspective).
- •Patients and/or a legal representative and their caregivers must have given informed consent. The legal representative and caregiver may be the same person.
- •Patient must have a reliable caregiver that is in frequent or daily contact with the patient, who will accompany the patient to the office and who will monitor the administration of prescribed medications. The caregiver will be able to communicate in English and be willing to comply with protocol requirements.
- •EXCLUSION CRITERIA
- •Patients must be excluded from this study if they meet any of the following criteria:
- •Secondary disorders inducing dementia such as neurosyphilis, craniocerebral trauma (CT/MRI), hyperthyroidism, or folic acid deficiency.
- •History of malignancy within 3 years, except for basal cell carcinoma.
- •History or diagnosis of symptomatic and/or unstable/uncontrolled:
- •Cardiovascular illnesses such as chronic congestive heart failure (with or without edema), arrhythmias, labile hypertension, ischemic heart disease, myocardial infarction (with residual angina), orthopnea, conduction defects (ECG), or other heart disease classified NYHA III or IV.
- •Liver disease such as cirrhosis, hepatitis B, hepatitis C, or primary or metastatic neoplasm.
- •Gastrointestinal disorder such as GI bleeding, malabsorption syndromes, post-gastrectomy, or active peptic ulcer disease.
- •Renal disease (primary or secondary) such as chronic renal failure (CLCR < 30 mL/min).
- •Endocrine disease such as diabetes mellitus or hypothyroidism.
- •Neurological disease (other than Dementia of the Alzheimer's Type such as Huntington's disease, Parkinson's disease, encephalitis, epilepsy, stroke, or multiple sclerosis) and psychiatric disorders such as schizophrenia, major depression, or mental retardation.
- •Significant pulmonary disease predisposing to hypoxia.
- •Immunological disorder such as clinically significant allergies, Lupus erythematosis, or scleroderma.
- •Hematological disease (regardless of cause) such as refractory anemia or refractory myelosuppression.
- •Organ system diseases which, in the opinion of the investigator, would impact on the primary and secondary endpoints of the trial such as dehydration (hematocrit >48%) or hypothyroidism.
- •Significant history of drug dependence or abuse (including alcohol, as defined in DSM IV or in the opinion of the investigator) within two years, or a positive urine drug screen for cocaine, heroin, or marijuana.
- •HIV positive.
- •Presence of Hepatitis C antibody.
- •Planned elective surgery requiring general anesthesia or hospitalization for more than 1 day during the study period.
- •Previous participation in any NS 2330 study.
- •Use of any investigational drug or procedure within 30 days before randomization.
- •Use of any drug within 14 days prior to randomization unless:
- •the dose of the drug and the condition being treated have been stable for at least 30 days and are expected to remain stable during the study
- •neither the drug nor the condition being treated is expected to interfere with the study endpoints.
- •Treatment with donepezil, galantamine, rivastigmine, or tacrine, is prohibited within 6 weeks before randomization.
- •Treatment with drugs that inhibit CYP 450 3A4 (see Appendix II for a list of relevant drugs.) If they are needed under emergency conditions, the patient should discontinue the trial.
- •Treatment with antipsychotics/neuroleptics is prohibited for 8 weeks prior to randomisation (see listing Appendix II).
- •Treatment with monoamine oxidase inhibitors is prohibited for 8 weeks prior to randomization.
- •Treatment with selective serotonin reuptake inhibitors is prohibited for 6 weeks prior to randomization.
- •Tricyclic antidepressants and antihistamines are prohibited for 4 weeks prior to randomization.
结局指标
主要结局
Changes in Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog)
时间窗: week 0, 4, 9, 14 and 20
次要结局
- comparison of study groups for drug plasma concentrations(weeks 0, 4, 9, 14 and 20)
- Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change(weeks 0 and 14)
- Alzheimer's Disease Cooperative Study-Activities of Daily Living(weeks 0, 4, and 14)
- Neuropsychiatric Inventory(weeks 0, 4, and 14)
- Mini-Mental State Examination(weeks 0 and 14)
- ADAS-Cog Extension(weeks 0, 4, 9, 14 and 20)
- ADAS-Cog total score including Extension(weeks 0, 4, and 14)
- types and frequencies of adverse events(20 weeks)
- proportion of patients discontinued from the trial because of adverse events(20 weeks)
- changes from baseline in vital signs(20 weeks)
- changes from baseline in laboratory measurements(20 weeks)
- changes from baseline in ECG readings(20 weeks)
- population PK parameters(Weeks 0, 4, 9, 14 and 20)
研究者
研究点 (87)
Loading locations...
相似试验
已完成
2 期
The Effects of Aplindore on the Treatment of Signs and Symptoms of Parkinson's DiseaseEarly Stage Parkinson's DiseaseNCT00623324Ligand Pharmaceuticals40
已完成
2 期
Safety, Tolerability, Pharmacokinetics and Activity of GS-9450 in Adults With Non-Alcoholic Steatohepatitis (NASH)Nonalcoholic SteatohepatitisNCT00740610Gilead Sciences124
招募中
2 期
A Study to Explore the Reasonable Dosage and Evaluate the Efficacy, Safety and Tolerability of HLX10 and HLX04 with or Without HLX53 in Untreated, Locally Advanced or Metastatic Hepatocellular Carcinoma Patients.Carcinoma, HepatocellularNCT06349980Shanghai Henlius Biotech117
已完成
1 期
The PK/PD Study of SHR7280 Tablets in Healthy Subjects.Healthy SubjectsNCT04554043Jiangsu HengRui Medicine Co., Ltd.118
已完成
2 期
Study of Vedolizumab Following Multiple Intravenous Doses in Patients With Ulcerative ColitisUlcerative ColitisNCT01177228Millennium Pharmaceuticals, Inc.47